Novozymes
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
| Company type | Aktieselskab |
|---|---|
| Nasdaq Copenhagen: NZYM B | |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | Bagsværd, Denmark |
Key people | |
| Products | Enzymes, microorganisms, biopharmaceutical ingredients |
| Revenue | 17.5 billion kr. (2022) |
| 4.56 billion kr. (2022) | |
| 3.69 billion kr. (2022) | |
| Total assets | 27.9 billion kr. (2022) |
| Total equity | 14.2 billion kr. (2022) |
Number of employees | 6,781 (2022) |
| Parent | Novo Holdings A/S |
| Website | novozymes |
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange.
On 12 December 2023, it was announced that Nozozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger, and on the following day, the name of the combined company was revealed as Novonesis.